Summary
The regulation of similar biotherapeutic products varies widely among the different Latin American countries. While some of them are yet to introduce their own regulation, others — like Brazil and Mexico — have opened ways to cheaper, complex and safe biological treatment for patients. However, many things need improving and a lot of experience is still necessary to develop a mature LATAM Biosimilars Market.
Biosimilars Latam – Mexico 2019 is a unique and effective meeting point to share the information and experience Latin America’s Pharmaceutical Industry needs to develop a dynamic and thriving biosimilars market.
Join us in Mexico and trigger a quantum leap in Latin American Healthcare!
Who will
you meet?
More than:
Participants
Companies
HCPs
Patients
Academy
Investors
Institutions
Associations
Service Providers
Government Agencies
Industry Executives from Latam
- Biosimilars
- Biobetters
- Biotechnology
- Biotherapeutics
- Analytical science
- Regulatory compliance
- Quality Control
- Clinical immunology
- Scientific Affairs
- Pharmacovigilance
- Research
- Regulatory
- Business Development
- Marketing
Speaker Board
Liliana Joachín Rodríguez
Quality and RA Director
Sergio Valentinotti
Life Science Director
Cecilia Bravo
CEO
Carlos Bertoncini
Innovation Project Director
Ector Jaime Ramirez
Diputado Federal LXIV Legislatura y secretario de la comisión de salud
Leah Christl
Executive Director, Global Regulatory and R&D Policy, JAPAC Lead and Global Biosimilars
Emilio Medina
Scientific Technical Director
Marielle Pascual Quintero
Expert in Regulatory Matters and Associate Professor
Nestor Lago
Medical Director
Vivian Lee
Director of Medical Affairs
Leonidas Unzueta
Medical Director
Nicolas Linares
VP & GM Mexico and Central America
Laura Palomares
Researcher and Professor
William Rodriguez Limas
Director of Biotechnology Development
Maria Fernanda Thees
Health Regulation and Surveillance Specialist
Nestor Perez
Operations Director
Oscar Gamiz
Marketing Head PS Latam
Eduardo Cioppi
Global Sales Director
Lori Daane
Director of Scientific Affairs
Ricardo Castro
VP of Bioprocessing
Biosimilars: Scientific evidence and its impact on patients
Current Development and Regulatory Challenges in Mexico
Nancy Huertas
Keralty, Colombia
Global Director of Pharmaceutical Affairs
Jorge García
BIOREDCOL, Colombia
President
EMA Experience with Biosimilar Approvals and Cross Border Utilisation
Regulatory Harmonisation Activities by Argentina, Brazil and Mexico
Pharmacovigilance. Signal Management. Safety Surveillance. Risk communication.
New Commercial Agreements in the region
Proposal to Revise the Regulation of Biosimilars in Mexico
Sponsors
Photo Gallery
Testimonials
-
”It was an excellent opportunity to hear what the authorities industry, even sometimes what our competitors or other providers have to say about the topic.”
Alison Bascou, Sr. Regulatory Director at BD, France
-
"I think it's being an interesting event. Wherever there's discussion at top level, wherever there's respect. wherever there's an open forum, science can advance. It's very important to keep patient's well-being in mind and I think this forum allows that."
Jaime Uribe, CEO At PROBIOMED
-
“The strength of the biosimilar industry in our region is very encouraging. It seems to me this event is the propitious forum to share experiences and it is great.”
Tammy Boggiano Ayo, Process Development Director at CIM, Cuba
-
“It showed a broad picture, from a highly technical perspective up to a commercial viewpoint. It is not easy to get that in such a short period of time.”
Santiago Salguero, Executive Director at Pharmaceutical Association of Ecuador
-
“For companies like those I work for, i.e. suppliers to the pharmaceutical industry, this has been a great opportunity to see our clients’ perspective and above all to identify the major trends determining the future of biosimilars.”
Mauricio Roberto Hernández Morales, Key Account and Business Developer Manager at BD Mexico